Gilead Sciences' Livdelzi Receives Accelerated FDA Approval For Primary Biliary Cholangitis
15/8 06:03
(RTTNews) - Gilead Sciences Inc. (GILD) announced that the U.S. Food and Drug Administration has granted accelerated approval for Livdelzi (seladelpar) to treat primary biliary cholangitis or PBC. Livdelzi can be used in combination with ursodeoxycholic acid or UDCA in adults who...